Phase 3 trial results show roflumilast cream 0.05% to be a safe and effective treatment for children with atopic dermatitis.

Once-daily roflumilast cream 0.05 percent is safe and effective for atopic dermatitis (AD) in patients ages 2 to 5 ye ...

Once-daily roflumilast cream 0.05% is safe and effective for atopic dermatitis (AD) in patients ages 2 to 5 years, according to a study published online Feb. 20 in Pediatric Dermatology.

Currently available fixed combination topicals have robust efficacy, and the recently approved cream formulations of tapinarof and roflumilast appear to have efficacy that may be higher than ...

Senores Pharmaceuticals through its wholly-owned subsidiary Senores Pharmaceuticals, Inc., USA (SPL) has signed an agreement to acquire the US FDA approved Abbreviated New Drug Application (ANDA) for ...

Data demonstrated favorable safety and local tolerability of ZORYVE® (roflumilast) cream 0.15% in adults and children with atopic dermatitis (AD) ...

The table is a review of notable updates that occurred in February 2025 for investigational products in development.

AlphaQuest LLC lessened its stake in shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT – Free Report) by 83.3% in the ...

One poster will share pooled INTEGUMENT data of ZORYVE® (roflumilast) cream 0.15% in atopic dermatitis (AD) in patients with prior inadequate response, intolerance, and/or contraindications to topical ...

Arcutis Biotherapeutics, Inc.’s ARQT share price has surged by 12.31%, which has investors questioning if this is right time to sell.

Senores Pharmaceuticals Limited announced the acquisition of US marketing rights for Roflumilast tablets through its American subsidiary. The deal with Breckenridge Pharmaceutical, Inc., a ...